Skip to main content
Top
Published in: Internal and Emergency Medicine 6/2018

01-09-2018 | CE - MEDICAL ILLUSTRATION

A rare and threatening complication in a cirrhotic patient

Authors: Joana Carvalho e Branco, Vera Anapaz, Liliana Santos, Jorge Reis

Published in: Internal and Emergency Medicine | Issue 6/2018

Login to get access

Excerpt

We present the case of a 72-year-old man with alcoholic cirrhosis Child–Pugh B (9 points) complicated by esophageal variceal bleeding in the past, hepatic encephalopathy (HE), and ascites. He was admitted to our department for HE. Laboratory analysis showed pancytopenia, INR 1.4, normal liver function tests, serum creatinine 3.56 mg/dL, urea 171 mg/dL, C-reactive protein of 8.39 mg/dL, bilirubin of 3.2 mg/dL and albumin of 2.74 mg/dL. On urinalysis, a leukocyturia was found; and on urine culture, Escherichia coli was isolated. Spontaneous bacterial peritonitis was excluded. Facing a decompensated liver cirrhosis Child–Pugh C (10 points) with hepatic encephalopathy in the context of urinary tract infection and acute kidney injury stage 3, he was started on ceftriaxone 2 g/day and albumin (60 g/day). After excluding other etiologies, hepatorenal syndrome type 1 was presumed. Despite initial improvement (creatinine 3.02 mg/dL) with the administration of albumin, 10 days later his creatinine reached a level of 4.9 mg/dL. Terlipressin was instituted in a dose of 1 mg every 6 h, which was optimized to 2 mg every 6 h due to lack of improvement. The day after this dose escalation, he developed skin necrosis on the tip of the first digit of the left foot (Fig. 1a), and cyanosis of all of the fingers of the right foot with initial signs of necrosis of the third, fourth and fifth digits (Fig. 1b). These changes were most likely due to terlipressin-induced skin necrosis; therefore, this medication was immediately stopped. Ischemic features improved in a few days with the complement of surgical debridement.
Literature
1.
go back to reference Moreau R, Durand F, Poynard T et al (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930CrossRefPubMed Moreau R, Durand F, Poynard T et al (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930CrossRefPubMed
2.
go back to reference Coskun B, Karaman A, Gorkem H, Bugday I, Poyrazoglu OK, Senel F (2014) Terlipressin-induced ischemic skin necrosis: a rare association. Am J Case Rep 15:476–479CrossRefPubMedCentral Coskun B, Karaman A, Gorkem H, Bugday I, Poyrazoglu OK, Senel F (2014) Terlipressin-induced ischemic skin necrosis: a rare association. Am J Case Rep 15:476–479CrossRefPubMedCentral
3.
go back to reference European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53(3):397–417CrossRef European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53(3):397–417CrossRef
4.
go back to reference Ramírez DD, Alonso SS, Palma MM (2011) Sildenafil in severe peripheral ischemia induced by terlipressin: a case report. Reumatol Clin 7:59–60CrossRef Ramírez DD, Alonso SS, Palma MM (2011) Sildenafil in severe peripheral ischemia induced by terlipressin: a case report. Reumatol Clin 7:59–60CrossRef
Metadata
Title
A rare and threatening complication in a cirrhotic patient
Authors
Joana Carvalho e Branco
Vera Anapaz
Liliana Santos
Jorge Reis
Publication date
01-09-2018
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 6/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1851-9

Other articles of this Issue 6/2018

Internal and Emergency Medicine 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.